News · Longevity & Aging
One protein at 12 weeks stood out from 2,904 as a signal of later preeclampsia
Preeclampsia is usually caught late, when the only treatment is delivery. Screening nearly 3,000 proteins in first-trimester blood produced one clear front-runner, and laboratory work suggests it is not just a marker.
- A single protein measured at about 12 weeks flagged later preeclampsia most strongly.
- It beat 2,903 other proteins tested in the same blood samples.
- The pattern repeated in two separate pregnancy cohorts.
- Laboratory work suggests the protein helps the placenta implant properly.
- This is a discovery study, not a test anyone can currently order.
Preeclampsia announces itself late. Blood pressure climbs, protein appears in the urine, and by the time those show up the problem has been developing for months. The only definitive treatment is delivering the baby, which is straightforward at 38 weeks and a serious decision at 28.
What everyone in the field wants is a signal early enough to act on. Something in the first trimester, when the placenta is still establishing itself and there is still time.
Writing in Nature Medicine, researchers went looking with a wide net. They performed proteomics in maternal serum taken at around 12 weeks of gestation and asked which of nearly three thousand proteins best flagged the pregnancies that would go wrong.
One protein out of 2,904
The answer was unusually clean. Low maternal serum isthmin-2 was the strongest protein signal for preeclampsia or fetal growth restriction, out of 2,904 measured.
Ranking first among nearly three thousand candidates in a single cohort could easily be chance. Screen enough proteins and something will top the list.
Which is why the validation matters more than the discovery. The association held in two independent cohorts, in different pregnancies with different blood samples, which is the step that separates a real signal from the winner of a lottery.
Why the placenta connection is the interesting part
A marker that predicts a disease is useful. A marker that is part of the disease is more useful, because it can be a target as well as a test.
Preeclampsia and fetal growth restriction are both associated with impaired invasion of the uterus by extravillous trophoblast, the placental cells that burrow into the uterine wall and rebuild the mother’s blood vessels to supply the pregnancy. When that process falls short, the placenta ends up underfed and the mother’s circulation carries the consequences.
Isthmin-2 turns out to be made almost entirely in the placenta, and within the placenta it is concentrated in exactly those invading cells.
The experiment that changes the claim
Correlation between a protein and an outcome tells you nothing about direction. So the researchers interfered with it directly.
Knocking down the protein in cultured human trophoblast stem cells profoundly inhibited invasion. Putting it into a cell line that does not normally make it promoted migration.
Take it away and the cells stop invading. Add it and they move. That is the shape of evidence that supports a causal role, and it lifts this above the long list of pregnancy biomarkers that predict something without explaining anything.
Cells in a dish are not a placenta. The step from here to a mechanism operating in a real pregnancy is real and unfinished.
What it would take to become a test
Being the strongest signal in a research cohort is not the same as being a useful screening test, and the gap between the two is where most biomarkers die.
A test needs a threshold, and thresholds trade false alarms against missed cases. It needs to perform in routine antenatal care rather than in a research setting with careful sampling. Most of all it needs an answer to the question of what a clinician does differently when the result comes back low.
That last point is not hypothetical for preeclampsia. Low-dose aspirin started early in pregnancy reduces risk in women identified as high risk, so there is already something to do with the information. A better way of choosing who gets it would matter.
Why the stakes are what they are
Preeclampsia is a serious blood pressure disorder that can develop during pregnancy and affects both mother and baby. Globally it is among the largest causes of maternal death, and fetal growth restriction sits alongside it as a major cause of stillbirth and newborn illness.
Both conditions currently get managed by watching for them. A first-trimester signal would change that to identifying them, which is a different kind of medicine.
This study does not deliver that. It delivers a strong candidate, replicated twice, with a plausible mechanism attached, which is roughly the best a discovery paper can do.
People also ask
What did the study find?
Low maternal serum isthmin-2 was the strongest protein signal out of 2,904 measured in first-trimester serum for later preeclampsia or fetal growth restriction. The association was validated in two independent cohorts, and the protein is produced almost exclusively in the placenta, enriched in extravillous trophoblast.
What is preeclampsia?
A pregnancy complication involving high blood pressure and signs of organ stress, usually after 20 weeks. It is a leading cause of maternal and newborn illness worldwide, and the definitive treatment is delivering the baby.
Why does a first-trimester signal matter?
Because the condition is currently detected once it is underway. A marker at 12 weeks would identify who to monitor closely and who might benefit from preventive treatment, well before anything is visible.
Is this a test I can get?
No. This is a discovery and validation study, not an approved clinical test. Turning a protein signal into a screening test requires separate work on thresholds, performance in routine care, and what clinicians should do with the result.
What makes it more than a marker?
The laboratory arm. Knocking down the protein in cultured human trophoblast stem cells profoundly inhibited invasion, and expressing it in cells that lack it promoted migration. That suggests involvement in the process rather than a bystander correlation.
What does trophoblast invasion have to do with it?
Both preeclampsia and fetal growth restriction are associated with the placenta failing to burrow properly into the uterine wall and remodel its blood supply. A protein that drives that invasion sits at the root of the problem rather than downstream of it.
What should someone who is pregnant take from this?
Nothing changes about current care. Existing blood pressure monitoring and risk assessment in pregnancy remain the way this is managed. This is general information rather than medical advice.